COVID-19 Severe Disease Progression Risk Profile
Use
Comprehensive panel for the assessment of patients at risk of severe COVID-19 disease progression
Special Instructions
Patients who are consuming high doses of biotin (vitamin B7) supplements are advised to stop at least 72 hours before the sample collection to avoid interference with test results. Care should be taken in patient preparation for accurate results.
Limitations
The Interleukin-6 test in this profile is not FDA approved but is authorized for use under an EUA for identifying severe inflammatory response related to COVID-19. It should be used in conjunction with existing clinical findings to assess risk accurately. There are risks of false positives leading to unnecessary intensive care and false negatives potentially delaying necessary treatments. Extremely high antibody titers may interfere with certain components of this panel, although minimization strategies are built into the test design.
Methodology
Immunoassay (Multiplex Protein Panel)
Biomarkers
LOINC Codes
- 164049
- 14804-9
- 2276-4
- 26881-3
- 33762-6
- 33959-8
- 1988-5
- 48065-7
- 6690-2
- 789-8
- 718-7
- 4544-3
- 787-2
- 785-6
- 786-4
- 788-0
- 777-3
- 770-8
- 736-9
- 5905-5
- 713-8
- 706-2
- 75652-8
- 751-8
- 731-0
- 742-7
- 711-2
- 704-7
- 71695-1
- 53115-2
- 58413-6
- 18314-5
Result Turnaround Time
2-4 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
5 mL
Minimum Volume
3.5 mL
Container
Gel-barrier tube
Collection Instructions
Blood should be collected in a gel-barrier tube, ensuring the tube is filled completely for proper chemical balance. Mix by inversion to ensure adequate anticoagulant distribution.
Storage Instructions
Freeze serum within four hours of collection and maintain frozen until testing.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | Room temperature |
| Frozen | Frozen |